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Abstract
Rationale—The abuse potential of opioids may be due to their reinforcing and rewarding effects,
which may be attenuated by neurokinin-1 receptor (NK1R) antagonists.
Objective—To measure the effects of opioid and neurokinin-1 (NK1R) receptor blockade on the
potentiation of brain stimulation reward (BSR) by morphine using the intracranial self-stimulation
(ICSS) method.
Methods—Adult male C57BL/6J mice (n = 15) were implanted with unipolar stimulating
electrodes in the lateral hypothalamus and trained to respond for varying frequencies of rewarding
electrical stimulation. The BSR threshold (θ0) and maximum response rate (MAX) were
determined before and after intraperitoneal administration of saline, morphine (1.0 - 17.0 mg/kg),
or the NK1R antagonists L-733,060 (1.0 - 17.0 mg/kg) and L-703,606 (1.0 - 17.0 mg/kg). In
morphine antagonism experiments, naltrexone (0.1 – 1.0 mg/kg) or 10.0 mg/kg L-733,060 or
L-703,606 was administered 15 minutes before morphine (1.0 - 10.0 mg/kg) or saline.
Results—Morphine dose-dependently decreased θ0 (maximum effect = 62% of baseline) and
altered MAX when compared to saline. L-703,606 and L-733,060 altered θ0 without affecting
MAX. 10.0 mg/kg L-733,060 and L-703,606, which did not affect θ0 or MAX, attenuated the
effects of 3.0 and 10.0 mg/kg morphine. 1.0 and 0.3 mg/kg naltrexone blocked the effects of 10.0
mg/kg morphine. Naltrexone given before saline did not affect θ0 or MAX.
Conclusions—The decrease in θ0 by morphine reflects its rewarding effects, which were
attenuated by NK1R and opioid receptor blockade. These results demonstrate the importance of
substance P signaling during limbic reward system activation by opioids.
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Morphine, an alkaloid isolated from the Papaver somniferum plant, has been widely used
since the early 19th century as an analgesic. In addition to its antinociceptive effects,
morphine and other opioid narcotics, such as heroin, fentanyl, and oxycodone, result in
euphoria and alleviate psychological distress (Goodman et al. 2011). It is therefore not
surprising that abuse of these drugs is a significant public health concern. According to the
National Center for Health Statistics, the number of deaths from the misuse of prescription
opioid analgesics has tripled from 1999 to 2006 (Warner et al. 2009), and approximately 1.7
million Americans meet the DSM-IV criteria for abuse or dependence of these drugs
(Substance Abuse and Mental Health Services Administration 2010). As part of a solution to
this problem, new pharmacological strategies are needed to diminish the reinforcing effects
of opioids and prevent their abuse.
Morphine is a potent agonist of the μ-opioid receptor (MOR), which is expressed in many
areas of the mammalian central nervous system, including the ventral tegmental area (VTA),
nucleus accumbens (NAc), periaquaductal grey, inferior colliculus, interpeduncular nucleus,
and the molecular layer of the cerebellum (Maurer et al. 1983). Opioid signaling in the VTA
and NAc alters activity of the mesolimbic dopamine system, which is hypothesized to
mediate the rewarding effects of drugs of abuse (Bozarth and Wise 1986; Kornetsky 1995).
In the VTA, MOR activation causes hyperpolarization of inhibitory interneurons (Johnson
and North 1992) and increases dopamine release in the NAc (Di Chiara and Imperato 1988;
Spanagel et al. 1990). This mechanism plays a critical role in reward perception and
behavioral reinforcement by opioids (Phillips and LePiane 1980; 1982; Spyraki et al. 1983).
The rewarding and reinforcing effects of morphine can be modeled in laboratory animals
using several behavioral conditioning techniques, including drug self-administration (Ross
et al. 1978; Wilson et al. 1971), conditioned place preference (CPP) (Mucha et al. 1982),
and intracranial self-stimulation (ICSS) (Kornetsky and Bain 1992; Olds and Milner 1954).
Intracranial self-stimulation is an operant behavioral method that measures the value of
electrical stimulation (brain stimulation reward or BSR) applied to the fibers of the medial
forebrain bundle (MFB) at the level of the lateral hypothalamus, and can be used to assess
the reward-potentiating or reward-devaluing effects of a drug (Olds and Milner 1954; Wise
1998). The MFB carries ascending dopaminergic fibers from the VTA to the NAc, as well as
descending glutamatergic fibers from the cortex to the pedunculopontine (PPN) and
dorsolateral tegmental nuclei (DLTg), which in turn send excitatory cholinergic projections
to the VTA (Wise 2005). Direct electrical stimulation of this pathway is potently reinforcing
(Valenstein and Campbell 1966), and results in release of dopamine in forebrain targets
(Cheer et al. 2007). Drugs of abuse enhance the activity of these fibers and reduce BSR
threshold, which is the minimum amount of electrical stimulation necessary to sustain
responding (Carlezon and Chartoff 2007; Kornetsky and Bain 1992).
The effects of opioid drugs on ICSS have been measured in rats (Esposito and Kornetsky
1977; Esposito et al. 1979; Holtzman 1976; Koob et al. 1975; Olds 1979; Schaefer and
Holtzman 1977) and mice (Bendani and Cazala 1988; Criswell 1982; Elmer et al. 1995;
Elmer et al. 2010). Early studies using a discrete trial-based procedure in rats demonstrated
that morphine lowers the threshold for ICSS responding at low doses but becomes aversive
at higher doses (Marcus and Kornetsky 1974). Interestingly, the acute reward-potentiating
effect of morphine does not sensitize with repeated administration (Esposito and Kornetsky
1977), although more recent studies have demonstrated that cycles of withdrawal from
heroin progressively raises baseline ICSS threshold (Kenny et al. 2006). Activation of the δ-
opioid receptor (DOR) and κ-opioid receptor (KOR) also alters ICSS responding. DOR
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agonists lower BSR threshold (Duvauchelle et al. 1996), whereas KOR agonists raise the
threshold (Todtenkopf et al. 2004).
Studies investigating the effects of morphine in C57BL/6J (C57) and DBA/2J (DBA) mice
have revealed distinct strain differences. Using a rate-dependent method of ICSS, Elmer at
al. (2010) found that C57 mice are sensitive to the reward-potentiating effects of morphine,
whereas DBA mice display elevations of BSR threshold suggestive of an aversion to the
drug. DBA mice also fail to self-administer morphine intravenously, which C57 mice do
readily (Elmer et al. 2010). These results are consistent with previous results that show that
C57 mice are more sensitive to the drug’s locomotor stimulating effects (Cunningham et al.
1992; Oliverio and Castellano 1974), although both strains readily acquire a place
preference to morphine paired environments (Cunningham et al. 1992).
Recent evidence has suggested that substance P (SP), a peptide neurotransmitter of the
tachykinin family, and its target, the neurokinin-1 receptor (NK1R), are involved in
modulating the rewarding effects of opioids (reviewed by (Commons 2010)). NK1R-null
mice on a C57 background (De Felipe et al. 1998) display morphine reward deficits in the
conditioned place preference model (CPP) (Gadd et al. 2003; Murtra et al. 2000) and self-
administer less morphine than wild type littermates (Ripley et al. 2002). However, animals
lacking NK1R display no difference in CPP or the self-administration of cocaine (Gadd et
al. 2003; Murtra et al. 2000) or food reinforcers (Murtra et al. 2000), suggesting that the
observed reward deficits are specific to opioids. In addition, these mice are less sensitive to
the locomotor-stimulating effects of morphine and fail to display behavioral sensitization to
morphine, but not cocaine (Ripley et al. 2002). Blockade of NK1 receptors could be one
approach to limiting the rewarding and reinforcing effects of morphine. In this study, we
investigated the ability of neurokinin-1 receptor antagonists to alter the rewarding effects of
morphine using ICSS. BSR thresholds were determined in C57 mice before and after
treatment with the opioid antagonist naltrexone, or after one of two NK1R antagonists,
L-733,060 and L-703,606. We also tested the ability of naltrexone, L-733,060, and
L-703,606 to alter the effects of morphine on BSR threshold. C57 mice were chosen for this
study because they exhibit robust responses to morphine with ICSS (Elmer et al. 2010) and
were used as the genetic background for NK1R deletion mutants (De Felipe et al. 1998).
METHODS
Mice
Male C57BL/6J mice (n = 15) were purchased from Jackson Laboratories (Bar Harbor, ME),
individually housed in polycarbonate cages (28 × 17 × 14 cm) with wire lids, and allowed to
acclimate to the vivarium for one week. Mice had free access to food and water throughout
all stages of the experiment and were housed in a vivarium kept at 21°C with a 12 hour
inverse light cycle (lights on at 8PM, off at 8AM). Cages were changed once a week, during
which time fresh bedding was provided. Animals were weighed at least once a week during
training and before every experimental session in which drug or vehicle was administered.
Three animals died before testing with L-703,606 (n = 10), and their brains were unavailable
for collection.
Surgery
The Institutional Animal Care and Use Committee (IACUC) of the University of North
Carolina approved all procedures, and they were conducted according to the Guide for the
Care and Use of Laboratory Animals (NIH publication No. 85-23, revised 2011). Mice were
anesthetized with ketamine (120 mg/kg) and xylazine (18 mg/kg) (Sigma, St Louis, MO),
and insulated monopolar stainless steel electrodes (0.28 mm diameter, Plastics One,
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Roanoke, VA) were stereotaxically-implanted in the right medial forebrain bundle at the
level of the lateral hypothalamus (coordinates: AP −1.2, ML −1.0, DV −5.0). The electrode
was grounded with a stainless steel skull screw and secured to the skull using dental cement.
A heating pad was used to maintain body temperature during the surgery and the first 30
minutes of recovery. Following surgery, animals were returned to their cages for one week
of recovery.
Apparatus
A sound-attenuating chamber (16 × 14 × 13 in, Med Associates, St Albans, VT) contained
an operant conditioning chamber with a grid floor (ENV-005A; Med Associates), wheel
manipulandum (ENV-113AM; Med Associates), and house light (ENV-315W; Med
Associates). Delivery of stimulation was controlled by MED-PC software for Windows
(version 4.1; Med Associates) and delivered via a stimulator (PHM-150B/2; Med
Associates) connected to a swivel commutator and insulated wire (Plastics One) that
attached to the stimulating electrode. A computer interface was connected to each box that
could record responses (1 response = ¼ turn of the wheel manipulandum), activate the house
light, and issue electrical current (BSR). Each stimulation was a 500 ms unipolar cathodal
square-wave current delivered at a trial-dependent frequency with 100 μs pulse width.
During the 500 ms stimulation period, wheel responses were recorded but did not earn
additional stimulation. Each response was accompanied by the illumination of the house
light as a secondary reinforcer.
Procedure
Following recovery from surgery, mice were conditioned to respond for BSR as previously
described (Malanga et al., 2008; Fish et al., 2010). During each day of drug testing, mice
responded during three consecutive 15-frequency series. Because responding during the first
series of each test day is variable, daily BSR thresholds (θ0) were calculated using responses
made during the 2nd and 3rd series. After baselines were recorded, mice were removed from
the conditioning chambers, injected with drug or saline, and placed in their home cages for
15 minutes, at the end of which mice were returned to the conditioning chambers and
allowed to respond during six series of frequencies (90 minutes total). Before any drugs
were administered, animals were habituated to saline injection in this manner on five
consecutive days. In all antagonist pre-treatment studies, a second injection of drug
(morphine) or saline was given 15 minutes after the first. The mice were then returned to the
conditioning chambers 15 minutes after the second injection and responses were measured.
In the first experiment, morphine sulfate (MS; 1.0 – 17.0 mg/kg, calculated as the sulfate
salt, i.p.) and the NK1R antagonists L-703,606 (1.0 – 17.0 mg/kg, i.p.) and L-733,060 (1.0 –
17.0 mg/kg, i.p.) were administered alone. The largest doses of L-703,606 and L-733,060
that were not reward-devaluing alone (i.e. did not increase BSR threshold) were chosen for
NK1R antagonist pre-treatment studies (10.0 mg/kg for both compounds). In the second
experiment, the daily baseline was determined; naltrexone (NTX, 0.1 – 1.0 mg/kg, i.p.) or
saline vehicle was given 15 minutes before morphine sulfate (1.0 – 10.0 mg/kg i.p.); and the
animals were allowed to respond during six subsequent 15-minute series. In the third
experiment, L-703,606, L-733,060, or saline was given 15 minutes prior to injection with
10.0 mg/kg morphine or saline (i.p.). MAX and θ0 were calculated for each post-injection
pass. For each experiment, a within-subjects design was used, and all mice received all drug
doses in random order unless otherwise noted. Because current intensity for ICSS training
and frequency range for ICSS testing is adjusted for each animal such that only the top 5-6
frequencies sustain responding, the mean baseline θ0 is reported as total charge delivered,
which is a function of both stimulus train frequency (Hz) and current (μA).
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Morphine sulfate, naltrexone, L-703,606, and L-733,060 were purchased from Sigma (St.
Louis, MO), dissolved in 0.9% saline, and injected intraperitoneally through a 27 gauge
needle at a volume of 1 ml/100 g body weight. All doses were calculated as their respective
salt. Within each experiment, all drugs and doses were administered in a counterbalanced
manner. Experiments were completed in the following order: single-drug testing (vehicle,
morphine sulfate, L-703,606, and L-733,060), acute naltrexone pre-treatment prior to
morphine, and acute NK1-receptor antagonist pre-treatment prior to morphine. No effect of
experiment order on post-injection θ0 or MAX following administration of morphine sulfate
or vehicle was found in these studies. Drug doses were chosen on the basis of previous
studies (Castellano and Puglisi-Allegra 1982; Elmer et al. 2010; Rupniak et al. 2000;
Thorsell et al. 2010).
Histology
At the end of the experiment, light microscopy was used to confirm the placement of the
most ventral tip of the stimulating electrode. 50 μm coronal brain sections were collected
from each animal after anesthesia with sodium pentobarbital (120 mg/kg i.p.) and
intracardial perfusion with 0.9% saline followed by 4% paraformaldehyde in 0.1 M
phosphate buffered saline. Sections were stained with cresyl violet for Nissl and the
electrode location was confirmed by direct visualization.
Statistical Analysis
All θ0 and MAX values were expressed as percent of pre-injection baseline for each animal.
For initial dose-response curves, one-way analysis of variance (ANOVA) tests were used to
detect significant effects of dose or time within groups. Post hoc Dunnett’s tests were used
to compare the effects of individual doses against vehicle (saline) values. For antagonist
studies, repeated measures ANOVA’s were used to compare the effects of drug and dose,
and post hoc 2-sided Dunnett’s tests were used to compare individual doses. As there were
no interaction between time and drug or dose in each single-drug and pre-treatment
experiment, percent of pre-injection baseline was averaged across six frequency series for
each experiment.
RESULTS
The electrode placements are shown in Figure 1. Of the 15 mice that were implanted, 13
were trained to spin the wheel within 2 sessions, and responding was robust following the
initial acquisition of the behavior. Although electrodes were implanted at the AP (skull,
relative to bregma) coordinate of −1.3, most tip locations were slightly caudal to this
location and sustained responding. The average baseline threshold (θ0) that sustained
responding in these mice prior to all drug experiments expressed as charge delivery was 0.51
μC (SEM = 0.062 μC). Two mice did not respond for electrical stimulation and were
excluded from testing. Throughout all experiments, mice responded in a frequency-
dependent manner (Figure 2).
Morphine Dose-Effects and Naltrexone Antagonism
When given alone, morphine dose-dependently lowered θ0 (Figure 3A) across 90 minutes of
testing (F(4, 66) = 25.0, p < 0.001). Post hoc analyses revealed that the 3.0, 10.0, and 17.0
mg/kg doses lowered θ0 when compared to saline vehicle, and the 1.0 mg/kg dose
approached significance (p = 0.052). Morphine also biphasically altered maximum response
rate (MAX; F(4, 66) = 4.4, p = 0.01; Figure 3B), although no doses were significantly
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different from vehicle. The 1.0, 3.0, and 10.0 mg/kg doses trended toward an increased
MAX, whereas the 17.0 mg/kg dose produced a trend toward a decreased MAX.
When 10.0 mg/kg morphine was administered following pre-treatment with saline or various
doses of naltrexone, the effect of morphine on θ0 depended on the naltrexone dose (F(3, 30)
= 7.9, p = 0.01; Figure 4A). Post-hoc analyses revealed that morphine lowered θ0 after
saline or the 0.10 mg/kg naltrexone dose but not after the 0.3 and 1.0 mg/kg doses. The 10.0
mg/kg morphine dose had no significant effect on MAX and did not interact with naltrexone
dose (F(3,30) = 0.74, p = 0.0.536; Figure 4B), although there was a significant main effect
of naltrexone pre-treatment on morphine-induced changes in MAX (F(3, 30) = 6.7, p =
0.027). No dose of naltrexone alone affected θ0 or MAX.
L-733,060 and L-703,606 Dose-Effects
When given alone, L-733,060 (F(4,57) = 4.2, p = 0.009) and L-703,606 (F(4,45) = 3.4, p =
0.016) altered θ0 when compared to saline vehicle (Figure 5A). Post hoc analysis revealed
that 17.0 mg/kg L-733,060 produced a significant increase in θ0. L-733,060 (F(4, 57) = 5.8,
p = 0.001), but not L-703,606, affected MAX when given alone (Figure 5B). Post hoc
analysis revealed that the 3.0 and 17.0 mg/kg doses decreased MAX. The 10.0 mg/kg dose
of these drugs had no significant effect on θ0 and MAX; this dose was used for pre-
treatment studies with morphine.
Pre-treatment with either 10.0 mg/kg L-733,060 (F(3,36) = 3.79, p = 0.018) or L-703,606
(F(3,27) = 5.22, p = 0.006) reduced morphine potentiation of BSR (Figure 6A) compared to
pre-treatment with saline. As compared to pre-treatment with saline, the effects of 3.0 and
10.0 mg/kg morphine were reduced by pre-treatment with 10.0 mg/kg L-733,060 or
L703,606. There was no difference in MAX between groups pre-treated with saline,
L-733,060, or L-703,606.
DISCUSSION
The reward-potentiating effects of morphine have been previously studied using the ICSS
technique (e.g. (Esposito and Kornetsky 1977; Esposito et al. 1979; Kornetsky 1995; Olds
1979; Schaefer and Holtzman 1977)). We examined the potentiation of brain stimulation
reward by morphine and investigated the ability of naltrexone and NK1R antagonists to alter
these effects. First, we observed that morphine lowers θ0 in C57 mice in a dose-dependent
manner using the curve shift method of ICSS (Carlezon and Chartoff 2007; Miliaressis et al.
1986), confirming previous observations (Elmer et al. 2010). Second, we found that the non-
selective opioid antagonist naltrexone attenuated the θ0-lowering effects of morphine,
confirming that this effect of morphine is reversible. This finding extends previous
observations in rats (Jenck et al. 1987) to C57 mice. Third, we observed that the NK1R
antagonists, L-733,060 and L-703,606, also attenuated the potentiation of BSR by morphine.
This finding supports those from other behavioral models of drug reward using NK1R-null
mutant mice (Murtra et al. 2000).
Morphine causes rapid and long-lasting changes in behavioral measures of reward (Wise
1989) and brain dopamine concentration (Murphy et al. 2001). Depending on the dose, acute
administration of morphine stimulates locomotor behaviors, an effect that is large in the C57
strain (Shuster et al. 1975b), and can induce both behavioral sensitization (Shuster et al.
1975a) and conditioned place-preference (Cunningham et al. 1992) when given repeatedly.
Acute morphine can also reduce the threshold for BSR (e.g. (Adams et al. 1972; Izenwasser
and Kornetsky 1987; Lorens and Mitchell 1973)). In the current study, doses between 1.0
and 17.0 mg/kg lowered θ0 across a 90 minute testing interval. This long duration of action
has been previously demonstrated (Izenwasser and Kornetsky 1987) and contrasts to the
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short-acting effects of alcohol and cocaine (Fish et al. 2010) on θ0 in C57BL/6J mice.
Elevations in brain dopamine follow a similar time course (Murphy et al. 2001) and it is
likely that they contribute to changes in BSR threshold (Cooper and Breese 1975; Koob et
al. 1978; Phillips and Fibiger 1978).
Morphine also appeared to have biphasic effects on maximum operant response rate. The
curve-shift method of ICSS is a rate-dependent measure of reward, and MAX provides
indirect information about locomotor activity (Schaefer and Holtzman 1977) and a direct
measure of the effect of a given drug on operant responding (Carlezon and Chartoff 2007). It
is possible that the increase in MAX that was observed over 1.0, 3.0, and 10.0 mg/kg doses
was indicative of psychomotor stimulation by morphine. However, elevations in maximum
response rate typically only occur during the highest frequencies and are not sustained
across each 15 minute series (see Figure 2), so it is unlikely that motor stimulation alone
could explain the changes in θ0. Additionally, 17.0 mg/kg morphine decreased MAX and
may have impaired responding, although much larger doses of morphine (40 mg/kg)
enhance locomotion in C57BL6/J mice (Shuster et al. 1975b). Further studies using both
lower and higher morphine doses would be needed to determine the mechanism of its
biphasic effects on maximum operant response rate.
The potent, long-acting opioid receptor antagonist naltrexone has been studied in several
animal models of reward and addiction-related behaviors. For example, it has been shown to
be reward-devaluing in ICSS (West and Wise 1988) and in the conditioned place-aversion
model (Parker and Rennie 1992), although ICSS results are mixed (reviewed by (Trujillo et
al. 1989)). Naltrexone also suppresses locomotion in C57BL/6J mice at doses of 1.0 mg/kg
or greater (Castellano and Puglisi-Allegra 1982). In the current study, there was no evidence
of elevated reward threshold or psychomotor depression when naltrexone was given alone,
suggesting that opioid receptor blockade is not reward-devaluing in the 0.1 – 1.0 dose range.
In contrast, naltrexone dose-dependently attenuated the reward-potentiating effects of
morphine. These results mirror findings that opioid receptor blockade diminishes behavioral
responses to morphine, such as ICSS responding (Schaefer and Michael 1981), locomotor
stimulation (Castellano and Puglisi-Allegra 1982; Frischknecht et al. 1983), reward
conditioning (Olmstead and Burns 2005; Olmstead and Franklin 1997; Piepponen et al.
1997; Shippenberg et al. 1996), and operant drug self-administration (Harrigan and Downs
1978).
The most significant result of the current study was that antagonism of the neurokinin-1
receptor attenuated the reward-potentiating effects of morphine without altering maximum
response rate, suggesting that distinct neural mechanisms mediate these rewarding effects
without affecting operant responding. Multiple findings suggest that substance P and opioid
signals interact in limbic reward pathways. Similar to opioids, SP or NK1R agonists increase
VTA dopaminergic neuron activity (Korotkova et al. 2006), enhance dopamine release in
the prefrontal cortex and NAc (Boix et al. 1995; Elliott et al. 1986; Elliott et al. 1991), and
produce locomotor stimulation (Elliott et al. 1991; Kelley et al. 1979). In the NAc, both SP
(Galarraga et al. 1999) and opioid peptides (Britt and McGehee 2008) alter medium spiny
neuron (MSN) output via actions on cholinergic interneurons, which may affect reward
states (Carlezon and Thomas 2009). Morphine also activates immediate early genes (e.g.,
Fos-B) in the NAc shell region, and this effect is absent in NK1R knockout mice (Murtra et
al. 2000). The amygdala, where MOR trafficking following morphine exposure is regulated
by NK1Rs ex vivo (Yu et al. 2009), also appears to be critical for opioid reward and
reinforcement, as ablation of NK1R-expressing neurons abolishes CPP to morphine (Gadd
et al. 2003). Most likely, NK1R blockade alters limbic reward circuit activation by morphine
and diminishes its rewarding effects. Alternatively, L-703,606 and L-733,060 could increase
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the aversive effects of morphine, although this is unlikely, given the known anxiolytic-like
effects of these drugs (reviewed by (Heilig et al. 2010)).
Human NK1R antagonists differ in their affinity and selectivity for the rodent NK1R, which
was an important consideration in this study. Geometry of the NK1R binding pocket differs
across species (Fong et al. 1992), and off-target antagonist binding sites include
neurokinin-2 and neurokinin-3 receptors, as well as L-type calcium channels (Seabrook et
al. 1996). L-733,060 has been shown to be effective in mice (Rupniak et al. 2000), although
its affinity for the rodent receptor (Kd = 550 nM) is lower than that of the human receptor
(Kd = 0.8 nM) (Seabrook et al. 1996). This drug binds NK1R in the striatum and amygdala
(Duffy et al. 2002), and modulates cocaine-evoked overflow of dopamine in the rat caudate
putamen (Kraft et al. 2001). L-703,606 also binds with higher affinity to the human NK1
receptor (Kd = 0.3 nM) than to the rat receptor (Kd = 300 nM) (Cascieri et al. 1992). It has
been used to block the rewarding effects of alcohol in C57BL/6J mice in a manner similar to
genetic deletion (Thorsell et al. 2010). Although non-specific effects of other NK1R
antagonists have been reported (Rupniak et al. 2001; Rupniak and Jackson 1994), L-733,060
and L-703,606 had similar reward-devaluing effects when given before morphine, making it
unlikely that off-target effects were responsible for behavioral observations reported here.
Although opioids are potent and widely-used analgesics used in the clinical management of
pain, they are also widely abused due to their rewarding effects. These effects, as measured
by changes in brain stimulation reward threshold, were attenuated by two different NK1R
antagonists. The cellular mechanisms by which L-733,060 and L-703,606 antagonize
morphine reward are not entirely clear, however, and await further investigation. New
techniques, such as optogenetic control of specific cell populations, may shed light on these
findings. Clinically, NK1R antagonists, which do not affect the antinociceptive effects of
morphine in animal models (Jasmin et al. 2002), could represent a viable strategy for
limiting the abuse potential of opioid analgesics. NK1R antagonists are well-tolerated by
human subjects (Quartara et al. 2009) and warrant further investigation into their potential
effectiveness in the treatment of substance abuse disorders.
Acknowledgments
This research was supported by R01-AA 018335 (CJM) and the NIAAA intramural research budget (MH).
Support: AA 018335 to CJM and the NIAAA intramural research funds to MH.
REFERENCES
Adams WJ, Lorens SA, Mitchell CL. Morphine enhances lateral hypothalamic self-stimulation in the
rat. Proc Soc Exp Biol Med. 1972; 140:770–1. [PubMed: 4556996]
Bendani T, Cazala P. Differential effects of intracerebral microinjection of morphine on approach and
escape responses induced by lateral hypothalamic stimulation in the mouse. Pharmacol Biochem
Behav. 1988; 30:397–401. [PubMed: 3174771]
Boix F, Sandor P, Nogueira PJ, Huston JP, Schwarting RK. Relationship between dopamine release in
nucleus accumbens and place preference induced by substance P injected into the nucleus basalis
magnocellularis region. Neuroscience. 1995; 64:1045–55. [PubMed: 7538637]
Bozarth MA, Wise RA. Involvement of the ventral tegmental dopamine system in opioid and
psychomotor stimulant reinforcement. NIDA Res Monogr. 1986; 67:190–6. [PubMed: 3092066]
Britt JP, McGehee DS. Presynaptic opioid and nicotinic receptor modulation of dopamine overflow in
the nucleus accumbens. J Neurosci. 2008; 28:1672–81. [PubMed: 18272687]
Carlezon WA Jr. Chartoff EH. Intracranial self-stimulation (ICSS) in rodents to study the
neurobiology of motivation. Nat Protoc. 2007; 2:2987–95. [PubMed: 18007634]
Robinson et al. Page 8













Carlezon WA Jr. Thomas MJ. Biological substrates of reward and aversion: a nucleus accumbens
activity hypothesis. Neuropharmacology. 2009; 56(Suppl 1):122–32. [PubMed: 18675281]
Cascieri MA, Ber E, Fong TM, Sadowski S, Bansal A, Swain C, Seward E, Frances B, Burns D,
Strader CD. Characterization of the binding of a potent, selective, radioiodinated antagonist to the
human neurokinin-1 receptor. Mol Pharmacol. 1992; 42:458–63. [PubMed: 1383685]
Castellano C, Puglisi-Allegra S. Effects of naloxone and naltrexone on locomotor activity in C57BL/6
and DBA/2 mice. Pharmacol Biochem Behav. 1982; 16:561–3. [PubMed: 6280203]
Commons KG. Neuronal pathways linking substance P to drug addiction and stress. Brain Res. 2010;
1314:175–82. [PubMed: 19913520]
Cooper BR, Breese GR. A role for dopamine in the psychopharmacology of electrical self-stimulation
of the lateral hypothalamus, substantia nigra, and locus coeruleus. Psychopharmacol Bull. 1975;
11:30–1. [PubMed: 1153654]
Criswell HE. A simple methodology for opiate self-administration and electrical brain stimulation in
the mouse. Life Sci. 1982; 31:2391–4. [PubMed: 6761530]
Cunningham CL, Niehus DR, Malott DH, Prather LK. Genetic differences in the rewarding and
activating effects of morphine and ethanol. Psychopharmacology (Berl). 1992; 107:385–93.
[PubMed: 1352057]
De Felipe C, Herrero JF, O’Brien JA, Palmer JA, Doyle CA, Smith AJ, Laird JM, Belmonte C,
Cervero F, Hunt SP. Altered nociception, analgesia and aggression in mice lacking the receptor for
substance P. Nature. 1998; 392:394–7. [PubMed: 9537323]
Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the
nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther. 1988;
244:1067–80. [PubMed: 2855239]
Duffy RA, Varty GB, Morgan CA, Lachowicz JE. Correlation of neurokinin (NK) 1 receptor
occupancy in gerbil striatum with behavioral effects of NK1 antagonists. J Pharmacol Exp Ther.
2002; 301:536–42. [PubMed: 11961054]
Duvauchelle CL, Fleming SM, Kornetsky C. Involvement of delta- and mu-opioid receptors in the
potentiation of brain-stimulation reward. Eur J Pharmacol. 1996; 316:137–43. [PubMed: 8982679]
Elliott PJ, Alpert JE, Bannon MJ, Iversen SD. Selective activation of mesolimbic and mesocortical
dopamine metabolism in rat brain by infusion of a stable substance P analogue into the ventral
tegmental area. Brain Res. 1986; 363:145–7. [PubMed: 2418910]
Elliott PJ, Mason GS, Stephens-Smith M, Hagan RM. Behavioural and biochemical responses
following activation of midbrain dopamine pathways by receptor selective neurokinin agonists.
Neuropeptides. 1991; 19:119–26. [PubMed: 1719444]
Elmer GI, Pieper JO, Goldberg SR, George FR. Opioid operant self-administration, analgesia,
stimulation and respiratory depression in mu-deficient mice. Psychopharmacology (Berl). 1995;
117:23–31. [PubMed: 7724699]
Elmer GI, Pieper JO, Hamilton LR, Wise RA. Qualitative differences between C57BL/6J and DBA/2J
mice in morphine potentiation of brain stimulation reward and intravenous self-administration.
Psychopharmacology (Berl). 2010; 208:309–21. [PubMed: 20013116]
Esposito R, Kornetsky C. Morphine lowering of self-stimulation thresholds: lack of tolerance with
long-term administration. Science. 1977; 195:189–91. [PubMed: 831268]
Esposito RU, McLean S, Kornetsky C. Effects of morphine on intracranial self-stimulation to various
brain stem loci. Brain Res. 1979; 168:425–9. [PubMed: 445153]
Fish EW, Riday TT, McGuigan MM, Faccidomo S, Hodge CW, Malanga CJ. Alcohol, cocaine, and
brain stimulation-reward in C57Bl6/J and DBA2/J mice. Alcohol Clin Exp Res. 2010; 34:81–9.
[PubMed: 19860803]
Fong TM, Yu H, Strader CD. Molecular basis for the species selectivity of the neurokinin-1 receptor
antagonists CP-96,345 and RP67580. J Biol Chem. 1992; 267:25668–71. [PubMed: 1281470]
Frischknecht HR, Siegfried B, Riggio G, Waser PG. Inhibition of morphine-induced analgesia and
locomotor activity in strains of mice: a comparison of long-acting opiate antagonists. Pharmacol
Biochem Behav. 1983; 19:939–44. [PubMed: 6657726]
Robinson et al. Page 9













Gadd CA, Murtra P, De Felipe C, Hunt SP. Neurokinin-1 receptor-expressing neurons in the amygdala
modulate morphine reward and anxiety behaviors in the mouse. J Neurosci. 2003; 23:8271–80.
[PubMed: 12967989]
Galarraga E, Hernandez-Lopez S, Tapia D, Reyes A, Bargas J. Action of substance P (neurokinin-1)
receptor activation on rat neostriatal projection neurons. Synapse. 1999; 33:26–35. [PubMed:
10380848]
Goodman, LS.; Brunton, LL.; Chabner, B.; Knollmann, BC. Goodman & Gilman’s the
pharmacological basis of therapeutics. 12th edn. McGraw-Hill; New York: 2011.
Harrigan SE, Downs DA. Continuous intravenous naltrexone effects on morphine self-administration
in rhesus monkeys. J Pharmacol Exp Ther. 1978; 204:481–6. [PubMed: 413904]
Heilig M, Thorsell A, Sommer WH, Hansson AC, Ramchandani VA, George DT, Hommer D, Barr
CS. Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to
curing the blues. Neurosci Biobehav Rev. 2010; 35:334–44. [PubMed: 19941895]
Holtzman SG. Comparison of the effects of morphine, pentazocine, cyclazocine and amphetamine on
intracranial self-stimulation in the rat. Psychopharmacologia. 1976; 46:223–7. [PubMed: 951457]
Izenwasser SE, Kornetsky C. Pharmacological effects of morphine on brain-stimulation reward.
Psychopharmacology (Berl). 1987; 93:136–7. [PubMed: 3114809]
Jasmin L, Tien D, Weinshenker D, Palmiter RD, Green PG, Janni G, Ohara PT. The NK1 receptor
mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline. Proc
Natl Acad Sci U S A. 2002; 99:1029–34. [PubMed: 11805341]
Jenck F, Gratton A, Wise RA. Opioid receptor subtypes associated with ventral tegmental facilitation
of lateral hypothalamic brain stimulation reward. Brain Res. 1987; 423:34–8. [PubMed: 2823990]
Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons.
J Neurosci. 1992; 12:483–8. [PubMed: 1346804]
Kelley AE, Stinus L, Iversen SD. Behavioural activation induced in the rat by substance P infusion
into ventral tegmental area: implication of dopaminergic A10 neurones. Neurosci Lett. 1979;
11:335–9. [PubMed: 514544]
Kenny PJ, Chen SA, Kitamura O, Markou A, Koob GF. Conditioned withdrawal drives heroin
consumption and decreases reward sensitivity. J Neurosci. 2006; 26:5894–900. [PubMed:
16738231]
Koob GF, Fray PJ, Iversen SD. Self-stimulation at the lateral hypothalamus and locus coeruleus after
specific unilateral lesions of the dopamine system. Brain Res. 1978; 146:123–40. [PubMed:
647383]
Koob GF, Spector NH, Meyerhoff JL. Effects of heroin on lever pressing for intracranial self-
stimulation, food and water in the rat. Psychopharmacologia. 1975; 42:231–4. [PubMed: 1161980]
Kornetsky C. Action of opioid drugs on the brain-reward system. NIDA Res Monogr. 1995; 147:33–
52. [PubMed: 8742780]
Kornetsky C, Bain G. Brain-stimulation reward: a model for the study of the rewarding effects of
abused drugs. NIDA Res Monogr. 1992; 124:73–93. [PubMed: 1470216]
Korotkova TM, Brown RE, Sergeeva OA, Ponomarenko AA, Haas HL. Effects of arousal- and
feeding-related neuropeptides on dopaminergic and GABAergic neurons in the ventral tegmental
area of the rat. Eur J Neurosci. 2006; 23:2677–85. [PubMed: 16817870]
Kraft M, Noailles P, Angulo JA. Substance P modulates cocaine-evoked dopamine overflow in the
striatum of the rat brain. Ann N Y Acad Sci. 2001; 937:121–31. [PubMed: 11458533]
Lorens SA, Mitchell CL. Influence of morphine on lateral hypothalamic self-stimulation in the rat.
Psychopharmacologia. 1973; 32:271–7. [PubMed: 4762234]
Marcus R, Kornetsky C. Negative and positive intracranial reinforcement tresholds: Effects of
morphine. Psychopharmacologia (Berl). 1974; 38:1–13.
Maurer R, Cortes R, Probst A, Palacios JM. Multiple opiate receptor in human brain: an
autoradiographic investigation. Life Sci. 1983; 33(Suppl 1):231–4. [PubMed: 6319868]
Miliaressis E, Rompre PP, Laviolette P, Philippe L, Coulombe D. The curve-shift paradigm in self-
stimulation. Physiol Behav. 1986; 37:85–91. [PubMed: 3016774]
Robinson et al. Page 10













Mucha RF, van der Kooy D, O’Shaughnessy M, Bucenieks P. Drug reinforcement studied by the use
of place conditioning in rat. Brain Res. 1982; 243:91–105. [PubMed: 6288174]
Murphy NP, Lam HA, Maidment NT. A comparison of morphine-induced locomotor activity and
mesolimbic dopamine release in C57BL6, 129Sv and DBA2 mice. J Neurochem. 2001; 79:626–
35. [PubMed: 11701766]
Murtra P, Sheasby AM, Hunt SP, De Felipe C. Rewarding effects of opiates are absent in mice lacking
the receptor for substance P. Nature. 2000; 405:180–3. [PubMed: 10821273]
Olds J, Milner P. Positive reinforcement produced by electrical stimulation of septal area and other
regions of rat brain. J Comp Physiol Psychol. 1954; 47:419–27. [PubMed: 13233369]
Olds ME. Hypothalamic substrate for the positive reinforcing properties of morphine in the rat. Brain
Res. 1979; 168:351–60. [PubMed: 312678]
Oliverio A, Castellano C. Genotype-dependent sensitivity and tolerance to morphine and heroin:
dissociation between opiate-induced running and analgesia in the mouse. Psychopharmacologia.
1974; 39:13–22. [PubMed: 4424979]
Olmstead MC, Burns LH. Ultra-low-dose naltrexone suppresses rewarding effects of opiates and
aversive effects of opiate withdrawal in rats. Psychopharmacology (Berl). 2005; 181:576–81.
[PubMed: 16010543]
Olmstead MC, Franklin KB. The development of a conditioned place preference to morphine: effects
of microinjections into various CNS sites. Behav Neurosci. 1997; 111:1324–34. [PubMed:
9438801]
Parker LA, Rennie M. Naltrexone-induced aversions: assessment by place conditioning, taste
reactivity, and taste avoidance paradigms. Pharmacol Biochem Behav. 1992; 41:559–65.
[PubMed: 1584835]
Phillips AG, Fibiger HC. The role of dopamine in maintaining intracranial self-stimulation in the
ventral tegmentum, nucleus accumbens, and medial prefrontal cortex. Can J Psychol. 1978; 32:58–
66. [PubMed: 737577]
Phillips AG, LePiane FG. Reinforcing effects of morphine microinjection into the ventral tegmental
area. Pharmacol Biochem Behav. 1980; 12:965–8. [PubMed: 7403209]
Phillips AG, LePiane FG. Reward produced by microinjection of (D-Ala2),Met5-enkephalinamide into
the ventral tegmental area. Behav Brain Res. 1982; 5:225–9. [PubMed: 7104089]
Piepponen TP, Kivastik T, Katajamaki J, Zharkovsky A, Ahtee L. Involvement of opioid mu 1
receptors in morphine-induced conditioned place preference in rats. Pharmacol Biochem Behav.
1997; 58:275–9. [PubMed: 9264103]
Quartara L, Altamura M, Evangelista S, Maggi CA. Tachykinin receptor antagonists in clinical trials.
Expert Opin Investig Drugs. 2009; 18:1843–64.
Ripley TL, Gadd CA, De Felipe C, Hunt SP, Stephens DN. Lack of self-administration and
behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors.
Neuropharmacology. 2002; 43:1258–68. [PubMed: 12527475]
Ross JW, Laska FJ, Fennessy MR. Brain biogenic amines and intravenous self-administration of
cocaine in rats. Clin Exp Pharmacol Physiol. 1978; 5:351–9. [PubMed: 699379]
Rupniak NM, Carlson EC, Harrison T, Oates B, Seward E, Owen S, de Felipe C, Hunt S, Wheeldon A.
Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal
vocalisation in guinea-pigs and mice. Neuropharmacology. 2000; 39:1413–21. [PubMed:
10818257]
Rupniak NM, Carlson EJ, Webb JK, Harrison T, Porsolt RD, Roux S, de Felipe C, Hunt SP, Oates B,
Wheeldon A. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of
the substance P (NK1 ) receptor in assays for antidepressant and anxiolytic drugs. Behav
Pharmacol. 2001; 12:497–508. [PubMed: 11742144]
Rupniak NM, Jackson A. Non-specific inhibition of dopamine receptor agonist-induced behaviour by
the tachykinin NK1 receptor antagonist CP-99,994 in guinea-pigs. Eur J Pharmacol. 1994;
262:171–5. [PubMed: 7529183]
Schaefer GJ, Holtzman SG. Dose- and time-dependent effects of narcotic analgesics on intracranial
self-stimulation in the rat. Psychopharmacology (Berl). 1977; 53:227–34. [PubMed: 19804]
Robinson et al. Page 11













Schaefer GJ, Michael RP. Threshold differences for naloxone and naltrexone in the hypothalamus and
midbrain using fixed ratio brain self-stimulation in rats. Psychopharmacology (Berl). 1981; 74:17–
22. [PubMed: 6791198]
Seabrook GR, Shepheard SL, Williamson DJ, Tyrer P, Rigby M, Cascieri MA, Harrison T, Hargreaves
RJ, Hill RG. L-733,060, a novel tachykinin NK1 receptor antagonist; effects in [Ca2+]i
mobilisation, cardiovascular and dural extravasation assays. Eur J Pharmacol. 1996; 317:129–35.
[PubMed: 8982729]
Shippenberg TS, Heidbreder C, Lefevour A. Sensitization to the conditioned rewarding effects of
morphine: pharmacology and temporal characteristics. Eur J Pharmacol. 1996; 299:33–9.
[PubMed: 8901005]
Shuster L, Webster GW, Yu G. Increased running response to morphine in morphine-pretreated mice.
J Pharmacol Exp Ther. 1975a; 192:64–7. [PubMed: 235638]
Shuster L, Webster GW, Yu G, Eleftheriou BE. A genetic analysis of the response to morphine in
mice: analgesia and runnimg. Psychopharmacologia. 1975b; 42:249–54. [PubMed: 1161983]
Spanagel R, Herz A, Shippenberg TS. The effects of opioid peptides on dopamine release in the
nucleus accumbens: an in vivo microdialysis study. J Neurochem. 1990; 55:1734–40. [PubMed:
1976759]
Spyraki C, Fibiger HC, Phillips AG. Attenuation of heroin reward in rats by disruption of the
mesolimbic dopamine system. Psychopharmacology (Berl). 1983; 79:278–83. [PubMed: 6405439]
Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey
on Drug Use and Health. In: Department of Health and Human Services. , editor. Summary of
National Findings. Vol. Volume I. Office of Applied Studies; Rockville, MD: 2010. http://
www.oas.samhsa.gov/NSDUH/2k9NSDUH/2k9Results.htm
Thorsell A, Schank JR, Singley E, Hunt SP, Heilig M. Neurokinin-1 receptors (NK1R:s), alcohol
consumption, and alcohol reward in mice. Psychopharmacology (Berl). 2010; 209:103–11.
[PubMed: 20112009]
Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr. Effects of kappa-opioid receptor ligands
on intracranial self-stimulation in rats. Psychopharmacology (Berl). 2004; 172:463–70. [PubMed:
14727002]
Trujillo KA, Belluzzi JD, Stein L. Opiate antagonists and self-stimulation: extinction-like response
patterns suggest selective reward deficit. Brain Res. 1989; 492:15–28. [PubMed: 2752295]
Valenstein ES, Campbell JF. Medial forebrain bundle-lateral hypothalamic area and reinforcing brain
stimulation. Am J Physiol. 1966; 210:270–4. [PubMed: 5901463]
Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the
United States, 1999-2006. NCHS Data Brief. 2009:1–8. [PubMed: 19796521]
West TE, Wise RA. Effects of naltrexone on nucleus accumbens, lateral hypothalamic and ventral
tegmental self-stimulation rate-frequency functions. Brain Res. 1988; 462:126–33. [PubMed:
3179728]
Wilson MC, Hitomi M, Schuster CR. Psychomotor stimulant self administration as a function of
dosage per injection in the rhesus monkey. Psychopharmacologia. 1971; 22:271–81. [PubMed:
4399836]
Wise RA. Opiate reward: sites and substrates. Neurosci Biobehav Rev. 1989; 13:129–33. [PubMed:
2573023]
Wise RA. Drug-activation of brain reward pathways. Drug Alcohol Depend. 1998; 51:13–22.
[PubMed: 9716927]
Wise RA. Forebrain substrates of reward and motivation. J Comp Neurol. 2005; 493:115–21.
[PubMed: 16254990]
Yu YJ, Arttamangkul S, Evans CJ, Williams JT, von Zastrow M. Neurokinin 1 receptors regulate
morphine-induced endocytosis and desensitization of mu-opioid receptors in CNS neurons. J
Neurosci. 2009; 29:222–33. [PubMed: 19129399]
Robinson et al. Page 12














Placement of intracranial self-stimulation monopolar electrodes in C57BL/6J mice.
Electrodes were aimed at the right medial forebrain bundle at the level of the lateral
hypothalamus (panel A). Black circles represent the most ventral position of the electrode
tip as detected by visual inspection of Nissl-stained brain sections using light microscopy
(panel B).
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Responding for different frequencies of brain stimulation reward for an individual C57BL/6J
mouse. Each response curve depict the effects of the following drug treatment combinations
on responding: saline/saline (open circles), saline/10.0 mg/kg morphine sulfate (gray
circles),1.0 mg/kg naltrexone/10.0 mg/kg morphine sulfate (black square), 10.0 mg/kg
L-733,060/10.0 mg/kg morphine sulfate (black triangle), or 10.0 mg/kg L-703,606/10.0 mg/
kg morphine sulfate (black diamond).
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Dose-response relationship for morphine on BSR threshold and maximum operant response
rate in C57BL/6J mice. BSR threshold (θ0, panel A) and maximum response rate (MAX,
panel B) are presented as mean (±1 SEM, vertical lines) percent of pre-injection baseline
after treatment with saline vehicle (white circle, n = 13) or morphine sulfate (grey circles;
1.0, 3.0, 10.0, and 17.0 mg/kg; n = 13). Asterisks indicate significance (p < 0.05) vs. saline
vehicle.
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Effect of naltrexone pre-treatment on morphine-induced changes in BSR threshold and
maximum response rate in C57BL/6J mice. BSR threshold (θ0, panel A) and maximum
response rate (MAX, panel B) are presented as mean (±1 SEM, vertical lines) percent of pre-
injection baseline after treatment with naltrexone followed by saline vehicle (white squares,
n = 13) or morphine sulfate (10.0 mg/kg, grey squares, n = 13). Asterisks indicate
significance (p < 0.05) vs. naltrexone alone.
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Dose-response relationship for the neurokinin-1 receptor (NK1R) antagonists L-733,060 and
L-703,606 on BSR threshold and maximum response rate in C57BL/6J mice. BSR threshold
(θ0, panel A) and maximum response rate (MAX, panel B) are presented as mean (±1 SEM,
vertical lines) percent of pre-injection baseline after treatment with saline (white circles, n =
13), L-733,060 (black triangles, n = 13), or L-703,606 (black diamonds, n = 10). Asterisks
indicate significance (p < 0.05) of L-733,060 dose vs. saline vehicle.
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Effect of L-733,060, L-703,606, or saline vehicle pre-treatment on morphine-induced
changes in BSR threshold and maximum response rate in C57BL/6J mice. BSR threshold
(θ0, panel A) and maximum response rate (MAX, panel B) are presented as mean (±1 SEM,
vertical lines) percent of pre-injection baseline after treatment with L-733,060 (10.0 mg/kg,
black triangles, n = 13), L-703,606 (10.0 mg/kg, black diamonds, n = 10), or saline vehicle
(grey circles, n = 13) followed by morphine sulfate. Asterisks indicate significance (p <
0.05) of morphine dose vs. vehicle.
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